OBJECTIVETo investigate the effect of Am80 on innate immune response of Porphyromonas gingivalis (Pg) W83-induced periodontitis in mice.

METHODSTwenty-five mice were randomly divided into five groups, control group, PgW83-induced periodontitis group (periodontitis), Am80 (10 µg/d) treatment group (low-dose group), Am80 (50 µg/d) treatment group (middle-dose group), Am80 (100 µg/d) treatment group (high-dose group). The distance of alveolar bone resorption in each mouse was observed and measured by a dissecting microscope. Enzyme-linked immunosorbent assay (ELISA) was used to detect the level of serum anti-Pg specific IgG. The mRNA expression of interferon-γ (IFN-γ) and interleuking-12 (IL-12) in gingival tissues, draining lymph node and spleen were detected by real-time reverse transcriptase polymerase chain reaction (RT-PCR). The measurement data were statistically analyzed.

RESULTSThe resorption rate in Am80 group [(121 ± 10)%] and high-dose of Am80 group [(108 ± 8)%] was significantly different with that in periodontitis mice [(133 ± 10)% ] (P < 0.05). The serum levels of anti-Pg specific IgG of the Am80 groups of different doses (0.437 ± 0.083, 0.566 ± 0.012, and 0.386 ± 0.078) were significantly lower than that of the periodontitis group (1.151 ± 0.433) (P < 0.001). Real-time quantitative PCR assay showed that after Am80 treatment, the IL-12 mRNA levels in the gingival tissues, lymph nodes and spleen of mice were reduced to 1.107 ± 0.088, 0.806 ± 0.220, and 0.668 ± 0.756, which were all significantly different with those in periodontitis (P < 0.01). Similarly, the relative expression of IFN-γ mRNA levels in gingival tissue, lymph nodes and spleen of mice were reduced to 8.898 ± 0.427, 16.654 ± 5.995, and 1.482 ± 0.033, which were significantly different with periodontitis (P < 0.001).

CONCLUSIONSAm80 can reduce the extent of inflammation and alleviate alveolar bone resorption by modulating innate immune response.